Jan 8
|
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 5
|
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
|
Jan 3
|
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 18
|
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU
|
Dec 8
|
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
|
Dec 5
|
PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
|
Dec 5
|
PTC Therapeutics (NASDAQ:PTCT) shareholders are up 17% this past week, but still in the red over the last three years
|
Sep 19
|
Analysts on Wall Street Lower Ratings for These 10 Stocks
|
Sep 15
|
Biotech Crashes 30% After European Regulators Yank Approval For Muscle Disease Drug
|
Sep 15
|
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
|
Sep 12
|
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
|
Sep 7
|
Is PTC Therapeutics (PTCT) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
|
Sep 7
|
Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy
|
Sep 7
|
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
|
Jul 18
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Jul 17
|
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
|
May 25
|
Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates
|
May 24
|
PTC Therapeutics' Barrage Of Bad News Is Good News For Rival Reata Pharmaceuticals — Here's Why
|
May 24
|
PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study
|
May 24
|
PTC Therapeutics Stock Tumbles: Company Stops Preclinical Gene Therapy Programs After Failed Friedreich's Ataxia Study
|